Alvotech expands manufacturing capacity for US biosimilar supply

Beactica Therapeutics has selected BEA-28 as a preclinical candidate in its TEAD program, which aims to develop new therapies for aggressive, hard-to-treat solid tumors, including cancers that have become resistant to existing treatments.

AstraZeneca has opened its newest global strategic R&D center in Kendall Square, Cambridge, Massachusetts. It is part of a USD 1 billion investment that will grow the company's workforce in the state by more than 50%.

The US FDA has extended its review of Novo's Biologics License Application for denecimig in haemophilia A, citing ongoing remediation work at a manufacturing facility. No new timeline for a decision has been communicated.

Hansa Biopharma has signed a collaboration with Amsterdam-based Cradle. Hansa will use Cradle's AI-driven protein design and engineering platform across its research and development work to develop new immunomodulatory treatments for severe autoimmune diseases.

Novo has cut the price of its obesity drug Wegovy in Sweden by 20%, effective October 1. Patients currently pay for the treatment out of pocket, and the company says the cut is meant to help more people stay on treatment over time.

Danish biotech Breye Therapeutics has closed an oversubscribed EUR 67.5 million Series A financing to advance danegaptide, its first-in-class oral treatment for non-proliferative diabetic retinopathy (NPDR), into a Phase II clinical trial.

Egetis Therapeutics has received FDA approval for Emcitate (tiratricol), making it the first approved treatment in the US for patients with the rare genetic disease MCT8 deficiency. With the approval, the company also received a Rare Pediatric Disease Priority Review Voucher.